In UM, a recent clinical trial (NCT04364230) investigated a combinatorial peptide vaccine approach incorporating six melanoma helper peptides (6MHP) and a mutated BRAF-derived peptide (NeoAg-mBRAF), co-formulated with immune adjuvants PolyICLC (a Toll-like receptor 3 agonist) and CDX-1140 (a CD40 agonist). Here, BRAF is linked to melanoma.